Document:

WWW.EXFILE.COM -- MATRITECH FORM 8-K -- EXHIBIT 4.2 -- 15357

    EXHIBIT
      4.2

    

    

    

    AMENDMENT

    TO

    CERTIFICATE
      OF DESIGNATIONS, PREFERENCES AND RIGHTS OF

    SERIES
      A
      CONVERTIBLE PREFERRED STOCK

    OF

    MATRITECH,
      INC.

    

    FILED
      IN
      THE SECRETARY OF

    STATE
      OF
      DELAWARE ON MARCH 4, 2005

    

     

    
 

    Matritech,
      Inc., a corporation organized and existing under and by virtue of the General
      Corporation Law of the State of Delaware (the “Corporation”),

    

    DOES
      HEREBY CERTIFY (Pursuant to Section 242 of the Delaware General Corporation
      Law):

    

    1.           The
      name of the Corporation is Matritech, Inc.;

    

    2.           That
      a Certificate of Designations, Preferences and Rights of Series A Convertible
      Preferred Stock of Matritech, Inc. (the “Certificate”) was filed with the
      Secretary of State of Delaware on March 4, 2005;

    

    3.           That
      pursuant to the provisions of Section 9 of the Certificate, the Certificate
      was
      previously amended on January 13, 2006 and January 19, 2007; and

    

    4.           That
      pursuant to the provisions of Section 9 of the Certificate, the Corporation
      and
      the holders of at least 75% of the outstanding Series A Preferred Stock have
      consented in writing to further amend the Certificate as follows:

    

    To
      delete subsection (c) of Section 6
      in its entirety and substitute in place thereof the following:

    

    “(c)  incur,
      assume or suffer
      to exist any indebtedness for borrowed money in excess of $15,300,000 in the
      aggregate, other than indebtedness incurred pursuant to a receivable or
      equipment lease financing and indebtedness outstanding on March 4,
      2005  which has not been subsequently amended to increase the amount
      of indebtedness or the interest rate applicable thereto;”

    

    IN
      WITNESS WHEREOF, said Matritech, Inc. has caused this Amendment to be signed
      by
      Stephen D. Chubb, its Chief Executive Officer, this 7th day of August,
      2007.

    

    

    MATRITECH,
      INC.

    

    

    By:
/s/
      Stephen D.
      Chubb                           

    Name:  Stephen
      D.
      Chubb

    Title:    Chief
      Executive OfficerWWW.EXFILE.COM -- MATRITECH FORM 8-K -- EXHIBIT 4.3 -- 15357

    EXHIBIT
      4.3

     

    

    CONSENT
      OF HOLDERS OF A MAJORITY OF OUTSTANDING PRINCIPAL VALUE OF 15% SECURED
      CONVERTIBLE PROMISSORY NOTES DATED JANUARY 13, 2006 AND DATED JANUARY 22, 2007
      TO DEFER PAYMENTS

    

    This
      Consent is executed and delivered on this 2nd day of August 2007 by the
      undersigned holders of a majority of the outstanding principal value of the
      15%
      Secured Convertible Promissory Notes issued by Matritech, Inc. (the
“Borrower”) on January 13, 2006 (the “Series A
      Notes”) pursuant to the Securities Purchase Agreement, dated as of
      January 13, 2006, by and among the Borrower and the purchasers party thereto
      and
      previously amended on January 22, 2007 and July 27, 2007 (the “Series A
      Purchase Agreement”) and the undersigned holders of a majority of the
      outstanding principal value of the 15% Secured Convertible Promissory Notes
      issued by the Borrower on January 22, 2007 (the “Series B
      Notes”) pursuant to the Securities Purchase Agreement, dated as of
      January 22, 2007, by and among the Borrower and the purchasers party thereto
      and
      previously amended on July 27, 2007 (the “Series B Purchase
      Agreement”).  The undersigned holders of a majority of the
      outstanding principal value of the Series A Notes shall be referred to as the
      “Series A Majority Holders.”  The undersigned holders
      of a majority of the outstanding principal value of the Series B Notes shall
      be
      referred to as the “Series B Majority
      Holders.”  All capitalized terms used in this Consent but not
      otherwise defined herein shall have the meanings ascribed to such terms in
      the
      Series A Purchase Agreement and the Series B Purchase Agreement,
      respectively.

    

    1.           Each
      undersigned Series A Holder hereby consents to the deferral of all payments
      of
      principal and interest due to the undersigned from the Borrower at any time
      on
      or after August 2, 2007 on the Series A Notes until the earlier of (a) a Change
      of Control of the Borrower (as defined in the Series A Notes) or (b) the
      Scheduled Maturity Date.

    

    2.           Each
      undersigned Series B Holder hereby consents to the deferral of all payments
      of
      principal and interest due to the undersigned from the Borrower at any time
      on
      or after August 2, 2007 on the Series B Notes until the earlier of (a) a Change
      of Control of the Borrower (as defined in the Series B Notes) or (b) the
      Scheduled Maturity Date.

    

    3.  
This
      Consent may be executed in multiple counterparts, each of which shall be deemed
      an original but all of which together shall constitute one and the same
      instrument, and by facsimile transmission or portable document format (“pdf”),
      which facsimile or pdf signatures shall be considered original executed
      counterparts.  This Consent shall be binding upon all Series A Holders
      and Series B Holders signing this Consent regardless of whether or not all
      other
      holders of Series A Notes and Series B Notes sign this Consent.

    

    

    [Remainder
      of Page Intentionally Left Blank]

     

     

     

     

     

     

     

     

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

    IN
      WITNESS WHEREOF, the undersigned Series A Majority Holders and the undersigned
      Series B Majority Holders have executed this Consent as of the day first above
      written.

     

    
 

    
      	
               

            	
              Holders:

            

    

    

    SDS
      Capital Group SPC, Ltd., on behalf of its

    Class
      D
      segregated portfolio

    

    By:
      /s/ Steve
      Derby                                           

    Name: 
      Steve Derby

    Title:    Director

    Series
      A
      Notes Held: $1,323,333  principal

    Series
      B
      Notes Held: $1,140,000 principal

    

     

     

    ProMed
      Partners, L.P.

    

    By:
      /s/ David B.
      Musket                                   

    Name:  David
      B. Musket

    Title:    Managing
      Director

    Series
      A
      Notes Held: $131,476  principal

    
      	
               

            	
              Series
                B Notes Held:
                $320,399  principal

            

    

     

    
 

    ProMed
      Partners II, L.P.

    

    By:
      /s/ David B.
      Musket                                   

    Name:  David
      B. Musket

    Title:    Managing
      Director

    
      	
               

            	
              Series
                B Notes Held:
                $16,816  principal

            

    

    

     

    
 

    ProMed
      Offshore Fund, Ltd.

    

    By:
      /s/ David B.
      Musket                                   

    Name:  David
      B. Musket

    Title:    Managing
      Director

    
      	
               

            	
              Series
                A Notes Held: $22,539 principal

            

    

    
      	
               

            	
              Series
                B Notes Held:
                $48,072  principal

            

    

    

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

    

    

    IN
      WITNESS WHEREOF, the undersigned Series A Majority Holders and the undersigned
      Series B Majority Holders have executed this Consent as of the day first above
      written.

     

    
 

    ProMed
      Offshore Fund II, Ltd.

    

    By:
      /s/ David B.
      Musket                                   

    Name: 
      David B. Musket

    Title:    Managing
      Director

    
      	
               

            	
              Series
                A Notes Held:
                $835,569  principal

            

    

    
      	
               

            	
              Series
                B Notes Held:
                $414,713  principal

            

    

    

     

    
 

    David
      B. Musket, Individually

    

    

    /s/
      David B.
      Musket                                          

    
      	
               

            	
              Series
                A Notes Held: $106,875 principal

            

    

    
      	
               

            	
              Series
                B Notes Held: $250,000 principal

            

    

    

     

    
 

    H&Q
      Life Science Investors

    

    By:
      /s/ Daniel R.
      Omstead                                 

    Name: 
      Daniel R. Omstead

    Title:   
      President

    
      	
               

            	
              Series
                A Notes Held:
                $1,583,333  principal

            

    

    
      	
               

            	
              Series
                B Notes Held:
                $1,000,000  principal

            

    

    

     

     

    The
      term
      H&Q Life Sciences Investors is the designation of the Trustees for the time
      being under a Declaration of Trust dated February 20, 1992, as amended, and
      all
      persons dealing with H&Q Life Sciences Investors must look solely to the
      trust property for the enforcement of any claims against H&Q Life Sciences
      Investors, and neither the Trustees, officers nor shareholders assume any
      personal liability for the obligations entered into on behalf of H&Q Life
      Sciences Investors.

     

     

     

     

     

     

    
      
        
        

      

      
        3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00128-of-00352.parquet"}]]